Suppr超能文献

生长激素分泌型垂体腺瘤患者接受兆伏级放疗后的激素及影像学效应

Hormonal and radiological effects of megavoltage radiotherapy in patients with growth hormone-secreting pituitary adenoma.

作者信息

Ciccarelli E, Valetto M R, Vasario E, Avataneo T, Grottoli S, Camanni F

机构信息

Dipartimento di Fisiopatologia, Università di Torino, Italy.

出版信息

J Endocrinol Invest. 1993 Sep;16(8):565-72. doi: 10.1007/BF03347671.

Abstract

Nineteen acromegalic patients (12 females and 7 males, aged 24-71 yr) were studied for 1-6 yr after radiotherapy (RT), administered by X-rays (18 MeV) by linear accelerator, with parallel opposite beams (doses 45-50.4 Gy, 1.8 Gy daily). Basal GH levels gradually decreased from 6.3-76.2 micrograms/L (mean +/- SE, 27.8 +/- 4.9) to 0.3-43.4 micrograms/L (11.7 +/- 3.6 micrograms/L; p < 0.005) at the last assessment. The earliest significant decrease was observed after one yr (14.9 +/- 3.8 micrograms/L; p < 0.005). Significant changes were observed also in IGF-I values (basal values 1.93-6.85 mU/ml, 3.22 +/- 0.30; last assessment 0.55-4.57 mU/mL, 1.58 +/- 0.31; p < 0.01). The earliest significant decrease of IGF-I values was observed after 2 yr (1.61 +/- 0.16 mU/ml; p < 0.005). GH levels < 5 micrograms/L together with normal IGF-I values were observed in 9 patients, 2-4 yr after RT. No changes were observed in PRL values, either in patients with pretreatment normal or elevated PRL levels. The CT and/or MRI picture of macroadenoma disappeared after 6-12 months in 3/12 patients. Moreover, a reduction (20-55%) in the diameter of the adenoma was shown after 6-36 months in other 4 patients. After RT 5/16 (31%) patients required cortisol and 4/19 (21%) thyroid replacement therapy. In 2/3 men a gonadal impairment was shown, that did not occur in the three female patients with normal gonadal function before RT.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

19例肢端肥大症患者(12例女性,7例男性,年龄24 - 71岁)在接受直线加速器产生的X射线(18 MeV)平行相对野放疗(RT)后,进行了1 - 6年的研究(剂量45 - 50.4 Gy,每日1.8 Gy)。基础生长激素(GH)水平从6.3 - 76.2微克/升(均值±标准误,27.8±4.9)逐渐降至末次评估时的0.3 - 43.4微克/升(11.7±3.6微克/升;p < 0.005)。最早在1年后观察到显著下降(14.9±3.8微克/升;p < 0.005)。胰岛素样生长因子-I(IGF-I)值也有显著变化(基础值1.93 - 6.85 mU/ml,3.22±0.30;末次评估0.55 - 4.57 mU/mL,1.58±0.31;p < 0.01)。IGF-I值最早在2年后观察到显著下降(1.61±0.16 mU/ml;p < 0.005)。放疗后2 - 4年,9例患者GH水平<5微克/升且IGF-I值正常。无论是治疗前PRL水平正常还是升高的患者,PRL值均无变化。12例患者中有3例在6 - 12个月后大腺瘤的CT和/或MRI影像消失。另外4例患者在6 - 36个月后腺瘤直径缩小(20 - 55%)。放疗后,16例患者中有5例(31%)需要皮质醇治疗,19例患者中有4例(21%)需要甲状腺替代治疗。2/3的男性出现性腺功能损害,而放疗前性腺功能正常的3例女性患者未出现这种情况。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验